Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 18, Issue 2, 2006, Pages 109-120

  Bachmann, M O ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

AFRICA, SOUTHERN; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; ISONIAZID; MARKOV CHAINS; MODELS, STATISTICAL; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS;

EID: 28844477477     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540120500159334     Document Type: Article

References (43)

1. Bachmann, M. O., & Booysen, F.L.R. (2003). Economic impact of HIV on South African households: cohort study. BioMed-Central Public Health, 3, 14.
2. Badri, M., Ehrlich, R., Pulerwitz, T., Wood, R., & Maartens, G. (2002). Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. International Journal of Tuberculosis and Lung Disease, 6, 231-237.
3. Bekker, L.G., Orrell, C., Reader, L., Matoti, K., Cohen, K., Martell, R., Abdullah, F., & Wood, R. (2003). Antiretroviral therapy in a community clinic - early lessons from a pilot project. South African Medical Journal, 93, 458-462.
4. Blower, S., Porco, T., & Lietman, T. (1998). Tuberculosis: the evolution of antibiotic resistance and the design of epidemic control strategies. In M. A. Horn, G. Simonett, & G. Webb (Eds.), Mathematical models in medical and health sciences (pp. 1-24). Nashville: Vanderbilt University Press.
5. Blower, S.M., Aschenbach, A.N., Gershengorn, H.B., & Kahn, J.O. (2001). Predicting the unpredictable: transmission of drug-resistant HIV. Nature Medicine, 7, 1016-1020.
6. Boulle, A., Kenyon, C., Skordis, J., & Wood, R. (2002). Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. South African Medical Journal, 92, 811-817.
7. Briggs, A. (2001). Handling uncertainty in economic evaluation. In M. Drummond, & A. McGuire (Eds.), Economic evaluation in health care (pp. 172-201). Oxford: Oxford University Press.
8. Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997). The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology, 50, 683-691.
9. Cleary, S., Boulle, A., McIntyre, D., & Coetzee, D. (2004). Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. http://www.hst.org.za (accessed 4 November 2005).
10. Clinton Foundation (2003). ARVS: Changing the economics of care and treatment. http://www.clintonfoundation (accessed 4 November 2005).
11. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., & Raviglione, M. C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV Epidemic. Archives of Internal Medicine, 163, 1009-1021.
12. Creese, A., Floyd, K., Alban, A., & Guiness, L. (2002). Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet, 359, 1635-1642.
13. Deeks, S. G. (2003). Treatment of antiretroviral-drug-resistant HIV-1I infection. Lancet, 362, 2002-2011.
14. Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., & Flepp, M. (1997). Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study - Swiss HIV Cohort Study. British Medical Journal, 315, 1194-1199.
15. Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, D., Cohen, C. J., & Seage, G. R. (2001). The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine, 344, 824-831.
16. Freedberg, K. A., Scharfstein, J. A., Seage, G. R., Losina, E., Weinstein, M. C., & Craven, D. E. (1998). The cost-effectiveness of preventing AIDS-related opportunistic infections. Journal of the American Medical Association, 279, 130-136.
17. Godfrey-Faussett, P., Maher, D., Mukadi, Y.D., Nunn, P., Perriëns, J., & Raviglione, M. (2002). How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bulletin of the World Health Organisation, 80, 939-945.
18. Grant, A.D., Kaplan, J.E., & De Cock, K.M. (2001). Preventing opportunistic infections among human immunodeficiency virus-infected adults in African countries. American Journal of Tropical Medicine and Hygiene, 65, 810-821.
19. Grimwade, K., & Swingler, G. (2003). Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV (Cochrane Review). In The Cochrane Library, Issue 3. Oxford: Update Software.
20. Hughes, J., Jelsma, J., Maclean, E., Darder, M., & Tinise, X. (2004). The health-related quality of life of peple living with HIV/AIDS. Disability and Rehabilitation, 26, 371-376.
21. Johnson, L. (2002). The ASSA Select Model. User Guide. Cape Town: Actuarial Society of Southern Africa. http://www.assa.org.za (accessed 20 August 2004)
22. Jordan, R., Gold, L., Cummins, C., & Hyde, C. (2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. British Medical Journal, 324, 1-10.
23. Kumaranayake, L., Grant, A.D., Roux, S., Charalambous, S., Day, J.H., & Rothwell, E. (2002). The cost of a clinic for HIV-infected employees in a workplace health service in Welkom, South Africa (Abstract). XIV International AIDS Conference, Barcelona, 7-12 July, 2002.
24. Kuntz, K., & Weinstein, M. (2001). Modelling in economic evaluation. In M. Drummond, & A. McGuire (Eds.), Economic Evaluation in Health Care (pp. 141-171). Oxford: Oxford University Press.
25. Maartens, G., Wood, R., O'Keefe, E., & Byrne, C. (1997). Independent epidemics of heterosexual and homosexual HIV infection in South Africa - survival differences. Quarterly Medical Journal, 90, 449-454.
26. Masobe, P., Lee, T., & Price, M. (1995). Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients - a least-cost analysis. South African Medical Journal, 85, 75-81.
27. Mocroft, A., Lederberger, B., Katlama, C., Kirk, O., Reiss, P., & D'Arminio, A. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 362, 22-29.
28. Mocroft, A. J., Lundgren, J. D., D'Arminio Monfiore, A., Lederberger, B., Barton, S. E., & Vella, S. (1997). Survival of AIDS patients according to type of AIDS-defining event. International Journal of Epidemiology, 26, 400-407.
29. Morgan, D., Mahe, C., Mayanja, B., Okongo, J. M., Lubenga, R., & Whitworth, J. A. G. (2002). HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared to that in industrialized countries? AIDS, 16, 597-603.
30. Morgan, D., Malamba, S. S., Orem, J., Mayanja, B., Okongo, M., & Whitworth, J. A. G. (2000). Survival by AIDS defining condition in rural Uganda. Sexually Transmitted Infection, 76, 193-197.
31. Mukadi, Y. D., Maher, D., & Harries, A. (2001). Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS, 15, 143-152.
32. Phillips, A. N., Lepri, A. C., Lampe, G., Johnson, M., & Sabin, C. A. (2003). When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS, 17, 1863-1869.
33. Schackman, B. R., Goldie, S. J., Weinstein, M., Losina, E., Zhang, H., & Freedberg, K. A. (2001). Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. American Journal of Public Health, 91, 1456-1463.
34. Sculpher, M. (2001). The role and estimation of productivity costs in economic evaluation. In M. Drummond, & A. McGuire (Eds.), Economic Evaluation in Health Care (pp. 94-442). Oxford: Oxford University Press.
35. Sinanovic, E., Floyd, K., Dudley, L., Azevedo, V., Grant, R., & Maher, D. (2003). Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease, 7, S56-62.
36. Song, F., Altman, D. G., Glenny, A. M., & Deeks, J. J. (2003). Validity of indirect comparison for estimating efficacy of competing interventions. British Medical Journal, 326, 472-475.
37. South African National Department Of Health (2003). Cabinet's Decision On The Operational Plan For Comprehensive Care And Treatment Of People Living With HIV And AIDS. http://www.doh.gov.za/docs/pr/2003/pr1119.html (accessed 4 November 2005).
38. TreeAge (2004). TreeAge Pro Healthcare Module User's Manual. Williamstown, MA: TreeAge Software Inc.
39. Uys, L. (2002). The cost of home-based terminal care for people with AIDS in South Africa. South African Medical Journal, 92, 624-628.
40. Wiktor, S.Z., Ekpini, E., Karon, J.M., Nkengasong, J., Maurice, C., & Severin, S.T. (1999). Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet, 353, 781-785.
41. Williams, B.G., & Dye, C. (2003). Anteretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science, 301, 1535-1537CD000171.
42. Woldehanna, S., & Volmink, J. (2004). Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). In The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd.
43. Wood, E., Braitstein, P., Montaner, M. T., Tyndall, M. W., O'Shaughnessy, M. V., & Hogg, R. S. (2000). Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet, 355, 2095-2100.